



PRESS RELEASE

January 18, 2023

Ziccum CEO to present at international mRNA Summit in Berlin

Lund, Jan 18, 2023 —Ziccum AB CEO Ann Gidner will present LaminarPace, the company's unique mass transfer drying methodology, at the mRNA-based Therapeutics Summit in Berlin 24 - 26 January. It is the leading European event for mRNA innovation expertise in Europe. On October 24, 2022 Ziccum announced that it had generated proof of successful nebulization and drying of vaccine lipid nanoparticles (LNP) in the latest stage of its ongoing in-house mRNA project. mRNA is the core strategic priority for the company.

On January 25th, Ziccum CEO Ann Gidner will present LaminarPace to an audience of senior Pharmaceutical industry decision makers, scientists and key opinion leaders in Berlin at an event described as 'the most comprehensive, industry-leading meeting for mRNA experts in Europe'.

mRNA in lipid nanoparticle (LNP) formulation is the break-through innovation that enabled mass-vaccination against Covid-19 around the globe. mRNA research and investment continues accelerating at great speed, and for Ziccum is the top strategic priority. LaminarPace, the company's ambient drying methodology based on the principle of mass transfer, efficiently turns liquid biopharmaceuticals into thermostable dry powders. In October 2022, Ziccum announced that it had nebulized and dried lipid nanoparticles (LNPs) in the latest stage of its proprietary mRNA project.

Ziccum's presentation is titled *LaminarPace: a novel unit operation successfully drying mRNA/LNP by mass transfer*. It will cover LaminarPace's unique ambient drying methodology based on the principle of mass transfer and how it dries liquid biopharmaceuticals into thermostable dry powders – a normally very challenging step - thanks to greatly reduced stress factors in the unique process.

It will describe how the well-defined dry powder delivered by LaminarPace can be reconstituted or used for novel administration routes, and how the system is being developed by Ziccum as a Pharmaceutical unit of production.

CEO Ann Gidner: "Our capabilities within mRNA could be a game changer for this innovative industry. Mass transfer drying, avoiding the difficulties of existing technologies and achieving thermostable formulations, could open up many new possibilities and opportunities. We look forward to sharing ideas with our colleagues in the field at this exciting event."

Book a meeting

with CEO Ann Gidner or Scientific Director Fabrice Rose
at the event [here](#).

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75

Ziccum's Certified Adviser is Erik Penser Bank AB

About Ziccum

Ziccum is developing new thermostable versions of vaccines and biologic materials for licensing to vaccine providers, developers and manufacturers in the global pharmaceutical industry. Ziccum's patented drying technology, LaminarPace, is unique. It formulates next-generation biomolecules at room temperature as particle-engineered powders that are thermostable and also highly suitable for novel administration routes. LaminarPace has formulated biomolecules from mRNA to proteins, peptides, antibodies, lipids and enzymes – and worked successfully with a range of excipients, adjuvants and antigens. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

[Ziccum CEO to present at international mRNA Summit in Berlin](#)